Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

onalespib (AT13387)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Otsuka

Drug class:

HSP90 inhibitor

Related drugs:

BRAF V600K	Solid Tumor	BRAF V600K	Solid Tumor	trametinib + dabrafenib + AT13387 Sensitive: C2 – Inclusion Criteria trametinib + dabrafenib + AT13387 Sensitive : C2	trametinib + dabrafenib + AT13387 Sensitive: C2 – Inclusion Criteria trametinib + dabrafenib + AT13387 Sensitive : C2
BRAF V600E	Solid Tumor	BRAF V600E	Solid Tumor	trametinib + dabrafenib + AT13387 Sensitive: C2 – Inclusion Criteria trametinib + dabrafenib + AT13387 Sensitive : C2	trametinib + dabrafenib + AT13387 Sensitive: C2 – Inclusion Criteria trametinib + dabrafenib + AT13387 Sensitive : C2
BRCA2 mutation	Ovarian Cancer	BRCA2 mutation	Ovarian Cancer	olaparib + AT13387 Sensitive: C3 – Early Trials olaparib + AT13387 Sensitive : C3	olaparib + AT13387 Sensitive: C3 – Early Trials olaparib + AT13387 Sensitive : C3
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	olaparib + AT13387 Sensitive: C3 – Early Trials olaparib + AT13387 Sensitive : C3	olaparib + AT13387 Sensitive: C3 – Early Trials olaparib + AT13387 Sensitive : C3